Eccogene (Shanghai) Co., Ltd

When AstraZeneca PLC scooped up an oral small molecule GLP-1 agonist from the Chinese firm Eccogene (Shanghai) Co., Ltd in November 2023, a sense of euphoria in China’s biotech sector marked the f

China represents a significant prospect in the respiratory space and AstraZeneca PLC believes it is the best placed company to capitalize on this opportunity. Pablo Panella, global head of respirato

AstraZeneca ’s recent run of success has heightened investor interest in the firm and its future growth as it prepares to unveil its long-term strategy next month. Better-than-expected Q1 results impr

Many once thought it an unrealistic goal, but AstraZeneca achieved full-year sales of more than $45bn in 2023, realizing a long-held ambition. Back in 2014, the then-new CEO Pascal Soriot boldly cla